Patient reported outcomes as endpoints in medical research

Statistical Methods in Medical Research

Volumn 13, Issue 2, 2004, Pages 115-138

  Fairclough, Diane L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOPIRAMATE;

CLINICAL STUDY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HEALTH STATUS; HUMAN; LONGITUDINAL STUDY; MEDICAL RESEARCH; MENTAL HEALTH; METHODOLOGY; MIGRAINE; OUTCOMES RESEARCH; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REVIEW; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; STATISTICAL ANALYSIS; VALIDATION PROCESS;

BIOMEDICAL RESEARCH; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; HUMANS; LONGITUDINAL STUDIES; MIGRAINE DISORDERS; SELF DISCLOSURE; TREATMENT OUTCOME; UNITED STATES;

EID: 1642284416     PISSN: 09622802     EISSN: None     Source Type: Journal    
DOI: 10.1191/0962280204sm357ra     Document Type: Review

References (73)

1. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life - a conceptual model of patient outcomes. Journal of the American Medical Association 1995; 273: 59-65.
2. Guyatt G, Feeny D, Patrick D. Issues in quality-of-life measurement in clinical trials. Controlled Clinical Trials 1991; 12 (4S): 81S-90S.
3. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: A quality adjusted survival analysis. Journal of Clinical Oncology 1989; 7: 36-44.
4. Glasziou PP, Simes RJ, Gelber RD. Quality adjusted survival analysis. Statistics in Medicine 1990; 9: 1259-76.
5. McNeil BJ, Weichselbaum R, Pauker SG. Tradeoffs between quality and quantity of life in laryngeal cancer. New England Journal of Medicine 1981; 305: 982-87.
6. Torrance GW, Thomas WH, Sackett DL. A utility maximizing model for evaluation of health care programs. Health Services Research 1971; 7: 118-33.
7. Feeny D, Furlong W, Barr RD, Torrance GW, Rosenbaum P, Weitzman S. A comprehensive multi-attribute system for classifying the health status of survivors of childhood cancer. Journal of Clinical Oncology 1992; 10: 923-28.
8. Weeks J. Quality-of-life assessment: Performance status upstaged? Journal of Clinical Oncology 1992; 10: 1827-29.
9. The EuroQoL Group. EuroQoL: A new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
10. Slevin ML, Plant H, Lynch D, Wilson P, Gregory WM, Armes PJ, Downer SM. Who should measure quality of life, the doctor or the patient? British Journal of Cancer 1988; 57: 109-12.
11. Loprinzi CL, Laurie JA, Wieand S, Krook JE, Novotny PJ, Kugler JW, Bartel J, Law M, Bateman M, Klatt NE. Prospective evaluation of prognostic variables from patient-completed questionnaires. Journal of Clinical Oncology 1994; 12: 601-607.
12. Coates A, Gebski V, Signorini D, Murray P, McNeil D, Byrne M, Forbes JF. Prognostic value of quality-of-life scores during chemotherapy for advance breast cancer. Journal of Clinical Oncology 1992; 10: 1833-38.
13. Wiklund I, Dimenas E, Wahl M. Factor of importance when evaluating quality of life in clinical trials. Controlled Clinical Trials 1990; 11: 169-79.
14. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl 7): 1-96.
15. Osterhaus JT, Townsend RJ, Gandek B, Ware JEJ. Measuring the functional status and well-being of patients with migraine headache. Headache 1994; 34: 337-43.
16. Solomon GD, Litaker DG. The impact of drug therapy on quality of life in headache and migraine. Pharmacoeconomics 1997; 11: 334-42.
17. Solomon GD. Evolution of the measurement of quality of life in migraine. Neurology 1997; 48 (Suppl 3): S1-15.
18. Mannix LK, Solomon GD. Quality of life in migraine. Clinical Neuroscience 1998; 5: 38-42.
19. Martin BC, Pathak DS, Kwong WJ, Batenhorst AS, Sharfman M. Assessment of responsiveness of the Migraine Specific Quality of Life Questionnaire (Version 2.1). Presented at Drug Information Association Sixth Annual Symposium of Contributed Papers on Quality of Life Evaluation, Hilton Head, March 29, 1999.
20. Martin BC, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P. Validity and reliability of the Migraine Specific Quality of Life Questionnaire. (MSQ Version 2.1). Headache 2000; 40: 204-15.
21. Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston, MA: Health Assessment Lab, New England Medical Center Health Institute, 1993.
22. Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Statistics in Medicine 1997; 16: 1197-1209.
23. Senn S, Stevens L, Chaturvedi N. Repeated measures in clinical trials: Simple strategies for analysis using summary measures. Statistics in Medicine 2000; 19: 861-77.
24. Ware J, Kosinski M, Keller DS. SF-36 Physical and mental component summary scales: A user's manual. Boston, MA: The Health Institute, New England Medical Center, 1994.
25. Ware J, Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: Summary of results from the Medical Outcomes Study. Medical Care 1995; 33: AS264.
26. Simon GE, Reviciki D, Grothaus L, Vonkorff M. SF-Summary Scores are physical and mental health truly distinct. Medical Care 1998; 36: 567-72.
27. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics 1979; 33: 321-36.
28. Hochberg Y. A sharper Bonferroni procedure for multiple significance testing. Biometrika 1988; 75, 800-803.
29. Westfall PH, Young SS. Resampling based multiple testing: examples and methods for p-value adjustments. NewYork, NY: John Wiley and Sons, Inc., 1993.
30. Marcus R, Pertz E, Gabrial KR. On closed testing procedures with special reference to ordered analysis of variance. Biometrika 1976; 63: 655-60.
31. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics 1984; 40: 1079-87.
32. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43: 487-98.
33. Zhang J, Quan H, Ng J, Stepanavage ME. Some statistical methods for multiple endpoints in clinical trials. Controlled Clinical Trials 1997; 18: 204-21.
34. Fetting JH, Gray R, Fairclough DL, Smith TJ, Margolin KA, Citron ML, Grove-Conrad M, Cella D, Pandya K, Robert N, Henderson IC, Osborne CK, Abeloff MD. Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: An Intergroup study. Journal of Clinical Oncology 1998; 16 (7): 2382-91.
35. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM. Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Quality of Life Research 1999; 8: 723-31.
36. Efron B, Feldman D. Compliance as an explanatory variable in clinical trials. Journal of the American Statistical Association 1991; 86: 9-17.
37. Shih WJ, Quan J. Testing for treatment differences with dropouts present in clinical trials - a composite approach. Statistics in Medicine 1997; 16: 1225-39.
38. Rubin DB. More powerful randomization-based p-values in double-blind trials with non-compliance. Statistics in Medicine 1998; 17: 371-85.
39. Angrist JD, Imbens GW, Rubin DB. Identification of causal effects using instrumental variables. Journal of the American Statistical Association 1996; 91: 444-55.
40. Newhouse JP, McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annual Review of Public Health 1998; 19: 17-34.
41. Little RJA. Modeling the dropout mechanism in repeated-measures studies. Journal of the American Statistical Association 1995; 90: 1112-21.
42. Fairclough DL, Peterson HF, Chang V. Why are missing quality of life data a problem in clinical trials of cancer therapy? Statistics in Medicine 1998; 17: 667-77.
43. Fairclough DL, Gagnon DD, Zagari MJ, Marschner N, Dicato M. Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients. Quality of Life Research 2003; 12: 1013-27.
44. Fairclough DL, Peterson HF, Cella D, Bonomi P. Comparison of several model-based methods for analysing incomplete quality of life data in cancer clinical trials. Statistics in Medicine 1998; 17 (5-7): 781-96.
45. Zwinderman AH. Statistical analysis of longitudinal quality of life data with missing measurements. Quality of Life Research 1992; 1: 219-24.
46. Little RJA. A test of missing completely at random for multivariate data with missing values. Journal of the American Statistical Association 1988; 83: 1198-1202.
47. Diggle PJ. Testing for random dropouts in repeated measurement data. Biometrics 1989; 45: 1255-58.
48. Engelman L. BMDP 8D: Correlations with missing data. In: Dixon WJ, ed. BMDP statistical software, Berkeley: University of California Press, 1990, pp 711-20.
49. Ridout MS. Testing for random dropouts in repeated measurement data. Biometrics 1991; 47: 1617-21.
50. Park T, Davis CS. A test of the missing data mechanism for repeated categorical data. Biometrics 1993; 49: 631-38.
51. Laird NM. Missing data in longitudinal studies. Statistics in Medicine 1988; 7: 305-15.
52. Jennrich RI, Schluchter MD. Unbalanced repeated-measures models with structured covariance matrices. Biometrics 1986; 42: 805-20.
53. Dixon WJ ed. BMDP statistical software manual, Vol 2. Berkeley: University of California Press, 1990.
54. The MIXED Procedure. SAS Technical Report P-229 SAS/STAT Software: Changes and Enhancements, Chap 16. Cary, NC: SAS Institute Inc., 1992, pp 289-366.
55. Fairclough DL. Quality of life in cancer clinical trials: Now that we have the data, what do we do? Journal of Applied Statistical Science 1996; 4 (4): 253-69.
56. Wu MC, Bailey KR. Analyzing changes in the presence of informative right censoring caused by death and withdrawal. Statistics in Medicine 1988; 7: 337-46.
57. Mori M, Woodworth GG, Woolson RF. Application of empirical Bayes inference to estimation of rate of change in the presence of informative right censoring. Statistics in Medicine 1992; 11: 621-31.
58. Troxel AB, Harrington DP, Lipsitz SR. Analysis of longitudinal data with non-ignorable non-monotone missing values. Applied Statistics 1998; 47: 425-38.
59. Smith DM, Robertson B, Diggle PJ. Object-oriented software for the analysis of longitudinal data in S. Technical Report MA96/192. Department of Mathematics and Statistics, University of Lancaster, LA1 4YfF United Kingdom.
60. Little RJA. A class of pattern-mixture models for normal incomplete data. Biometrika 1994; 81, 471-83.
61. Curren D. Analysis of incomplete longitudinal quality of life data, Doctoral dissertation. Linburgs Universitair Centrum, June 2000.
62. Diggle PJ, Kenward MG. Informative dropout in longitudinal data analysis (with discussion). Applied Statistics 1994; 43: 49-93.
63. Wu MC, Carroll RJ. Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process. Biometrics 1988; 44: 175-88.
64. Schluchter MD. Methods for the analysis of informatively censored longitudinal data. Statistics in Medicine 1992; 11: 1861-70.
65. DeGruttola V, Tu XM. Modeling progression of CD4-lymphocyte count and its relationship to survival time. Biometrics 1994; 50: 1003-14.
66. Ribaudo HJ, Thompson SG, Allen-Mersh TG. A joint analysis of quality of life and survival using a random effects selection model. Statistics in Medicine 2000; 19: 3237-50.
67. Heyting A, Tolboom JTBM, Essers JGA. Statistical handling of dropouts in longitudinal clinical trials. Statistics in Medicine 1992; 11: 2043-61.
68. Gould AL. A new approach to the analysis of clinical drug trials with withdrawals. Biometrics 1980; 36: 721-27.
69. Lavori PW, Dawson R, Shera D. A multiple imputation strategy for clinical trials with truncation of patient data. Statistics in Medicine 1995; 14: 1913-25.
70. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987.
71. Rubin DB, Schenker N. Multiple imputation in health-care data bases: An overview and some applications. Statistics in Medicine 1991; 10: 585-98.
72. Schafer JL. Analysis of incomplete multivariate data. New York: Chapman and Hall, 1997.
73. Crawford SL, Tennstedt SL, McKinlay JB. A comparison of analytic methods for nonrandom missingness of outcome data. Journal of Clinical Epidemiology 1995; 48: 209-19.